uniQure (NASDAQ:QURE) Shares Gap Up – What’s Next?

uniQure N.V. (NASDAQ:QURE) shares gapped up before the market opened on Monday. The stock had previously closed at $24.83, but opened at $26.22. uniQure shares last traded at $23.3850, with a volume of 1,996,815 shares traded.

Analysts Set New Price Targets

Several analysts have recently issued reports on QURE shares. Wolfe Research raised shares of uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 price target on the stock in a research report on Wednesday, July 29th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $75.00 price target on shares of uniQure in a research report on Tuesday, September 29th. UBS Group started coverage on shares of uniQure in a research report on Thursday, October 15th. They issued a “buy” rating and a $48.00 price target for the company. William Blair raised shares of uniQure to a “strong-buy” rating in a report on Wednesday, September 23rd. Finally, Weiss Ratings upgraded shares of uniQure from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, September 21st. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, uniQure presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.25.

uniQure Stock Performance

The company has a market capitalization of $1.66 billion, a PE ratio of -5.98 and a beta of 1.14. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.01 and a current ratio of 10.01. The company has a 50 day moving average price of $34.55 and a 200 day moving average price of $29.67.

Hedge Funds Weigh In On uniQure

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Seven Fleet Capital Management LP bought a new stake in shares of uniQure during the 2nd quarter worth $15,254. IFP Advisors Inc grew its holdings in shares of uniQure by 39.8% in the 2nd quarter. IFP Advisors Inc now owns 2,780 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 791 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of uniQure in the third quarter worth about $86,000. Fulton Bank N.A. acquired a new position in uniQure during the second quarter valued at approximately $220,000. Finally, Activest Wealth Management bought a new stake in uniQure in the third quarter valued at approximately $121,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.

uniQure’s best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement.